ReviewOncology letters2026
Progress in perioperative immunotherapy for lung cancer and analysis of therapy (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical treatment has long been the preferred approach for lung cancer. In recent years, postoperative adjuvant immunotherapy following surgical treatment has demonstrated good efficacy. Building on this foundation, the introduction of neoadjuvant immunotherapy prior to surgery has also reported promising results in a number of clinical trials. The aim of the present review was to summarize recent research findings associated with perioperative immunotherapy for lung cancer, including key outcomes from both neoadjuvant and adjuvant therapies. The discussion of the results of the present review primarily addressed efficacy, safety, survival data and programmed death-ligand 1 subgroup analyses. Furthermore, the advantages and limitations of different treatment modalities, including monotherapies and combination therapies, were discussed. Furthermore, the present review incorporated discussions on the applicability of biomarkers in perioperative immunotherapy, the role of immunotherapy combined with other treatments during the perioperative period, mechanisms of resistance and potential solutions to these challenges. In conclusion, the present review offers a systematic examination of the theoretical foundations of perioperative immunotherapy for lung cancer, simultaneously presenting key clinical evidence (including neoadjuvant therapy, adjuvant therapy and 'sandwich' combination regimens), diverse combination strategies (chemotherapy and radiotherapy), the current status of biomarker applications and challenges in underlying drug resistance mechanisms for perioperative immunotherapy. It proposes a dynamic monitoring model and clinical decision pathway for omission of adjuvant immunotherapy in non-small cell lung cancer. Lastly, based upon the latest evidence-based medical research, the present review aims to provide clinicians and researchers with comprehensive decision-making references and scientific guidance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.